{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-306915","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.543740+00:00","generated_at":"2026-05-16T15:22:04.405305+00:00","sec_items":["3.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026","bullets":["Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.","CEO expects FDA meeting later in 2025 to discuss clinical/regulatory pathways for acute kidney injury.","Company plans to start Phase 2/3 AKI study in 2026, building manufacturing and CRO infrastructure.","Stockholders approved share issuance related to warrants; warrant expiration fixed to Dec 3, 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-306915","json":"https://secwatch.observer/filing/0001193125-25-306915.json","markdown":"https://secwatch.observer/filing/0001193125-25-306915.md","text":"https://secwatch.observer/filing/0001193125-25-306915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525306915/0001193125-25-306915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525306915/revb-20251203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:22:04.405305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}